EirGenix Inc.
TWO: 6589.TWO0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Taipei Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Lee-Cheng Liu
- Employees
- 1,000
- Headquarters
- New Taipei City, Taiwan
- IPO year
- 2016
- Market cap
- NT$13.7B
- Website
- https://www.eirgenix.com
Loading 6589…
Loading profile data…Frequently asked questions about 6589
What does EirGenix Inc. (6589.TWO) do?
EirGenix Inc. operates as a contract development and manufacturing company in Taiwan and internationally. The company offers cell line development, process development, analytical and quality control, cGMP manufacturing mammalian and microbial system, and antibody-drug conjugate services. It is also involved in the development of EG12014/EGI014,...
Where does 6589.TWO trade?
EirGenix Inc. (6589.TWO) trades on the Taipei Exchange.
What sector is 6589.TWO in?
EirGenix Inc. (6589.TWO) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of EirGenix Inc.?
Lee-Cheng Liu is the chief executive officer of EirGenix Inc. (6589.TWO).
Where is EirGenix Inc. headquartered?
EirGenix Inc. is headquartered in Taiwan.
Does 6589.TWO pay a dividend?
EirGenix Inc. (6589.TWO) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 6589.TWO go public?
EirGenix Inc. (6589.TWO) completed its initial public offering in 2016.